For the Future
New Biologics Business
New biotech business (cell therapy)
Hybrid Structure for Business Operations
Virtual business structure and Project management
Establishment of Cell Therapy Platform
IR Policy / Disclaimer
Please refer to the "Company Profile"
Please refer to the "History"
GTS promotes a development of bio medicine products without having manufacturing facilities.
From the early stage, we have focused on the future potential of biosimilar product and realized G-CSF (Filgrastim BS).
For further details, please refer to the "Features /Strength"
For the differences between new bio medicine and biosimilars, please refer to the following "Bio Medicine Products and the Market".
Bio medicine products are medicines originating from biological processes, and the pharmacological effects that can not be achieved with existing small molecule drugs are attracting attention.
According to the report issued by METI (Ministry of Economy, Trade and Industry in Japan), the market for bio medicine products has reached more than $ 75 billion in 2007 and accounted for more than 10% of the world's pharmaceuticals market in 2007. Among the top 10 products in the global drug sales market, the number of bio medicine product from only 1 in 2000 to four in 2007. In addition, 22 bio medicine products account for over $ 1 billion in sales. "(Source: Report by Ministry of Economy, Trade and Industry (June, 2010)) .
Biosimilar is a product with the same or similar quality as new bio medicine products, which have already been approved for marketing. The new bio medicine products will reach the timing of patent expiration, biosimilar is expected to form a large market globally in the future.
Please refer to the latest financial result in "IR Information"
Please refer to the latest financial forecast in "Topics"
Please refer to the "IR Calendar"